Home Merck Announces Second-Quarter 2014 Financial Results
 

Keywords :   


Merck Announces Second-Quarter 2014 Financial Results

2014-07-29 12:56:00| Merck.com - Corporate News

Dateline City: WHITEHOUSE STATION, N.J. Second-Quarter 2014 Non-GAAP EPS of $0.85, Excluding Certain Items, and GAAP EPS of $0.68 2014 Full-Year Non-GAAP EPS Target of $3.43 to $3.53, Excluding Potential Venezuelan Bolivar Devaluation and Certain Other Items; 2014 Full-Year GAAP EPS Target of $4.44 to $4.77 2014 Full-Year Non-GAAP EPS Target Includes $0.06 to $0.09 Anticipated Dilution From Planned Sale of Merck Consumer Care and Research Collaboration With Bayer, and Planned Acquisition of Idenix Generated Worldwide Sales of $10.9 Billion, a Decrease of 1 Percent, Reflecting Unfavorable Impact of Patent Expiries, Divested Products and Decline in Sales of Hepatitis C Products Grew Top Five Franchises by 6 Percent in Total Pembrolizumab (MK-3475), an Investigational Anti-PD-1 Antibody, Accepted in Second Quarter for Regulatory Review in Both the United States and European Union WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced financial results for the second quarter of 2014. Language: English Contact: MerckMedia:Steve Cragle, 908-423-3461Lainie Keller, 908-423-4187orInvestors:Joe Romanelli, 908-423-5185Justin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: results financial announces merck

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news

»
26.06Atlantic Tropical Weather Outlook
26.06Eastern North Pacific Tropical Weather Outlook
26.06Fox and The Trade Desk extend ad integrations across Fox's portfolio
26.06XREAL bring Play Store apps to 3D space on XREAL AR glasses
26.06Qwilt reveals live streaming survey results
26.06Rockline Industries Wins WOW Innovation Award
26.06IMS Technologies Expands Calcinate Production Site
26.06Horizon expert 'gave evidence based on informal chats'
More »